Multaq

Treatment for Atrial Fibrillation, Atrial Flutter

Update: Multaq Now FDA Approved - July 1, 2009

FDA Advisory Committee Recommends Approval of Multaq

FDA Advisory Committee Recommends Approval of Multaq (dronedarone)

PARIS, March 18, 2009 /PRNewswire-FirstCall/ --Sanofi-aventis announced today that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favor of the approval of Multaq by the U.S. Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF).

As demonstrated in the ATHENA trial, Multaq is the only anti-arrhythmic drug to have shown in a clinical study a significant reduction in morbidity and mortality in patients with atrial fibrillation/atrial flutter (AFL) or a recent history of these conditions.

"said Jean-Pierre Lehner, Chief Medical Officer, sanofi-aventis."

The FDA is not bound by the Committee's recommendation, but it takes its advice into consideration when reviewing new drug applications.

Atrial fibrillation is the leading cause of hospitalization for arrhythmia in the U.S. and represents one-third of hospitalizations for arrhythmia in Europe. Hospitalization due to AF has increased dramatically (two-to-three fold) in recent years in the U.S. Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality. There are approximately 2.5 million Americans and 4.5 million people in the European Union with atrial fibrillation and it is emerging as a growing public health concern due to an aging population.

Multaq, an investigational treatment discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 6,700 patients. Multaq is one of the major therapeutic innovations in atrial fibrillation for the last twenty years. Multaq has been granted a priority review by the U.S. Food and Drug Administration (FDA) and a registration dossier is also under regulatory review by the European Medicines Agency (EMEA).

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York . For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com.

Media Contact: Marisol Peron, 908.981.6565, mobile: 908-672-9051, marisol.peron@sanofi-aventis.com

CONTACT: Marisol Peron, +1-908-981-6565, mobile: +1-908-672-9051, marisol.peron@sanofi-aventis.com

Web site: http://www.sanofi-aventis.com/http://www.sanofi-aventis.us/

Ticker Symbol: (NYSE:SNY),(NYSE:SNY)

Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: March 2009

Related Articles

Multaq (dronedarone) FDA Approval History

View comments

Hide
(web5)